MIRA
INFORM REPORT
|
Report Date : |
20.11.2006 |
IDENTIFICATION
DETAILS
|
Name : |
ZENESES
BIOSCIENCES PRIVATE LIMITED |
|
|
|
|
Formerly Name: |
Vas Qramedies Biotech Private Limited |
|
|
|
|
Registered Office : |
C-52,
Rohit Kunj, Pitampura, Delhi –110 034 |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as on) : |
31.03.2005 |
|
|
|
|
Date of Incorporation : |
03.12.2003 |
|
|
|
|
Com. Reg. No.: |
55-123302 |
|
|
|
|
CIN No.: [Company
Identification No.] |
U24239DL2003PTC123302 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
DELZ00417E |
|
|
|
|
Legal Form : |
Private
Limited Liability Company |
|
|
|
|
Line of Business : |
Manufacturers and Suppliers of
Medicines, Healthcare Products, Veterinary Medicines, Veterinary Formulations |
RATING & COMMENTS
|
MIRA’s Rating : |
Ca |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of
interest and principal sums in default or expected to be in default upon
maturity |
Limited with full security |
|
Maximum Credit Limit : |
|
|
|
|
|
Status : |
Moderate
|
|
|
|
|
Payment Behaviour : |
Unknown
|
|
|
|
|
Litigation : |
Unknown
|
|
|
|
|
Comments : |
Subject
appears to be a small and unknown company having moderate track. No trade
references and payments records and known. The
company can be considered for small to mediocre business dealings on safe and
secured trade terms and conditions. |
LOCATIONS
|
Registered Office : |
C-52,
Rohit Kunj, Pitampura, Delhi –110 034 |
|
|
|
|
Corporate
Office : |
18, First Floor, Deep Cinema
Commercial Complex, Ashok Vihar, Phase-I, Delhi-110052 |
|
Tel.
No.: |
91-11-2744 1121, 2744 1127 |
|
Fax
No.: |
91-11-2744 2468, 2746 0019 |
|
E-Mail
: |
|
|
Website : |
DIRECTORS
|
Name : |
Mr.
Sameer Geol |
|
Designation : |
Director |
|
Address : |
152-D,
Kamla Nagar, Delhi – 100 007 |
|
Date of Birth/Age : |
02.05.1975 |
|
Date of Appointment : |
03.12.2003 |
|
|
|
|
Name : |
Mr.
Vipul Goel |
|
Designation : |
Director |
|
Address : |
152-D,
Kamla Nagar, Delhi – 100 007 |
|
Date of Birth/Age : |
30.05.1978 |
|
Date of Appointment : |
03.12.2003 |
MAJOR SHAREHOLDERS
|
Names
of Shareholders |
No. of Shares |
Percentage of Holding |
|
Mr.
Sameer Geol |
5,000 |
50.00 |
|
Mr.
Vipul Goel |
5,000 |
50.00 |
|
Total |
10,000 |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturers and Suppliers of
Medicines, Healthcare Products, Veterinary Medicines, Veterinary Formulations |
|
|
|
|
Exports to : |
Africa and Russia. |
GENERAL
INFORMATION
|
Bankers : |
Not
Available |
|
|
|
|
Facilities : |
-- |
|
|
|
|
Banking Relations : |
Unknown
|
|
|
|
|
Auditors : |
M/s
Pankaj Pawan & Associates Chartered
Accountants |
|
Address: |
103-Professors’
Lane, Kurukshatra Road, Kaithal |
|
Tel. No.: |
91-1746-234943 |
|
|
|
|
Associates/Subsidiaries : |
Nil |
CAPITAL STRUCTURE
Authorised
Capital :
|
No.
of Shares |
Type |
Value |
Amount |
|
100,000 |
Equity
Shares |
Rs. 10/- Each |
Rs. 1.000 Millions |
Issued,
Subscribed & Paid-up Capital :
|
No.
of Shares |
Type |
Value |
Amount |
|
10000 |
Equity
Shares |
Rs. 10/- Each |
Rs. 0.100 Millions |
FINANCIAL DATA
[all figures are in Rupees
Millions]
ABRIDGED
BALANCE SHEET
|
SOURCES OF FUNDS |
|
31.03.2005 |
31.03.2004 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
|
0.100 |
0.100 |
|
|
2] Share Application Money |
|
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
|
0.000 |
0.000 |
|
|
4] (Accumulated Losses) |
|
(0.072) |
(0.016) |
|
|
NETWORTH |
|
0.028 |
0.084 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
|
0.000 |
0.000 |
|
|
2] Unsecured Loans |
|
0.014 |
0.014 |
|
|
TOTAL BORROWING |
|
0.014 |
0.014 |
|
|
DEFERRED TAX LIABILITIES |
|
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
|
0.042 |
0.098 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
|
0.000 |
0.000 |
|
|
Capital work-in-progress |
|
0.000 |
0.000 |
|
|
|
|
|
|
|
|
INVESTMENT |
|
0.000 |
0.000 |
|
|
DEFERREX TAX ASSETS |
|
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
|
0.000 |
0.000 |
|
|
Sundry Debtors |
|
0.000 |
0.000 |
|
|
Cash & Bank Balances |
|
0.025 |
0.100 |
|
|
Other Current Assets |
|
0.025 |
0.000 |
|
|
Loans & Advances |
|
0.000 |
0.000 |
|
Total Current Assets |
|
0.050 |
0.100 |
|
|
Less : CURRENT LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Current Liabilities & Provisions |
|
0.008 |
0.002 |
|
|
|
|
|
|
|
Total Current Liabilities |
|
0.008 |
0.002 |
|
|
Net Current Assets |
|
0.042 |
0.098 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
|
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
|
0.042 |
0.098 |
|
PROFIT
& LOSS ACCOUNT
|
PARTICULARS |
|
31.03.2005 |
31.03.2004 |
|
Sales Turnover [including other income] |
|
0.000 |
0.000 |
|
|
|
|
|
|
Profit/(Loss)
Before Tax |
|
(0.058) |
(0.008) |
|
Provision
for Taxation |
|
0.000 |
0.000 |
|
Profit/(Loss)
After Tax |
|
(0.058) |
(0.008) |
|
|
|
|
|
|
Total
Expenditure |
|
0.058 |
0.008 |
KEY
RATIOS
|
PARTICULARS |
|
|
31.03.2005 |
31.03.2004 |
|
PAT / Total Income |
(%) |
|
(47.54) |
(6.90) |
|
|
|
|
|
|
|
Return
on Investment (ROI) (PBT/Networth) |
|
|
(58.00) |
(8.00) |
|
|
|
|
|
|
|
Quick Ratio |
|
|
6.25 |
50.00 |
|
|
|
|
|
|
|
Debt Equity Ratio |
|
|
0.14 |
0.14 |
|
|
|
|
|
|
|
Current Liabilities/Networth |
|
|
0.08 |
0.02 |
LOCAL AGENCY
FURTHER INFORMATION
Zeneses has expanded the range of its products on the market and enjoys acknowledgement and recognition among both doctors and patients. At present the company offers medications from all the basic therapeutic categories for people in different ages with different needs.
The company is constantly making new investments with a view of constant
growth. Since its founding, Zeneses has been fulfilling its mission, whose
primary objective is to provide doctors, pharmacists and patients with
affordable medicines of highest quality and therapeutic efficiency. Using data from
the local market as well as comparative marketing data from American and
Western European markets, they thoroughly researches and analyses the clients'
needs so that it can quickly respond to them with a product that will perfectly
meet their expectations.
In the fields of production, technology, and development, their company
cooperates with carefully chosen partners. Combining reliable pharmaceutical
knowledge with high quality technology, Zeneses offers medicines which are both
therapeutically efficient and trusted by patients.
The products offered by Zeneses guarantee their patients safety and ease of
use. All the packages have always been provided with detailed information even
if it wasn't required by law. Moreover, they are additionally protected from
being accidentally used by children, and in terms of size, they are adjusted to
people's needs.
In accordance with the adopted corporate strategy, their company strives to
meet the expectations of its users, i.e. patients, doctors, and pharmacists, by
providing them with reliable information wherever they expect it. Zeneses takes
numerous informational and educational actions aimed at doctors and pharmacists
supplying them with all the data needed to provide their patients with
exhaustive and trustworthy information on their medicines. Thanks to such
actions doctors and pharmacists are aware that they have safe and effective
drugs at their disposal, which they can recommend to their patients with full
confidence.
In order to facilitate quick and efficient response to market needs, their
company has developed a sales and distribution system enabling effective and
well-organized sales, good trade practices, and excellent relations with
clients.
Zeneses is a fast growing company, serving a vital and important role in the
pharmaceutical market. Through many years, they have developed a tried and true
formula for success.
Zeneses uses and applies strict and uncompromising GMP standards in the
manufacturing, production and packaging of all its products.
They are committed to offering only the very best pharmaceutical products to
their consumers and health care professionals together with unsurpassed
marketing support. They have come to expect the best and the finest from us.
Their success has been made possible, thanks to the effort of their people.
They have attracted the finest talent and given them the environment to perform
and excel.
Because of their creativity, innovation, marketing skills, accumulated
expertise and talented people, they are very excited by their bright prospects
for the future in the world market.
The performance of the Company has proven their belief that a well integrated,
market driven company, with the right products, could succeed in an emerging
economy.
VISION AND MISSION STATEMENT
The Vision of Zeneses is to become the best pharmaceutical company - a model to
be followed by their competitors.
The Mission of Zeneses is to provide the best products, which enhance health,
well-being and vitality of people and, as a result, place us at the top of the
pharmaceutical business.
THEIR COMMITMENT
To Consumers
They believe that their first responsibility is to consumers who use their
products. To meet their needs everything they do is of the highest quality.
They constantly strive to reduce their costs in order to maintain reasonable
prices. As a result, their products are not only effective and safe, but also
accessible and competitive on the market.
To Health Care Professionals
They cooperate very closely with medical and pharmaceutical authorities and
follow the latest research and trends in their industry. They continuously stay
in touch with the leading technical experts on the production of
pharmaceuticals. The combination of sound pharmaceutical knowledge and their
state of the art technology expertise has resulted in the development of
effective products that are trusted by millions of consumers.
To Business Partners
They build trust and solid relations with their business partners, suppliers on
one side and distributors and retailers on the other, dealing with them with
the highest standards of professionalism, integrity and ethics.
To Employees
They are committed to their employees, the highly dedicated men and women who
work with us. Everyone is respected as an individual and is recognized for
their merit.
To Community
They are responsible to the community and society in which they live and work.
They believe and support strong community commitments and involvement with
charities and social campaigns.
CMT REPORT [Corruption, Money
laundering & Terrorism]
The
Public Notice information has been collected from various sources including but
not limited to: The Courts, India Prisons Service, Interpol, etc.
1] INFORMATION
ON DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court
Declaration :
No records exist to suggest that subject is or was the subject of any
formal or informal allegations, prosecutions or other official proceeding for
making any prohibited payments or other improper payments to government
officials for engaging in prohibited transactions or with designated parties.
3] Asset
Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record
on Financial Crime :
Charges or conviction registered
against subject: None
5] Records
on Violation of Anti-Corruption Laws :
Charges or investigation registered
against subject: None
6] Records
on Int’l Anti-Money Laundering Laws/Standards :
Charges or investigation registered
against subject: None
7] Criminal
Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation
with Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation
Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA
INFORM as part of its Due Diligence do provide comments on Corporate Governance
to identify management and governance. These factors often have been predictive
and in some cases have created vulnerabilities to credit deterioration.
Our
Governance Assessment focuses principally on the interactions between a
company’s management, its Board of Directors, Shareholders and other financial
stakeholders.
CONTRAVENTION
Subject
is not known to have contravened any existing local laws, regulations or
policies that prohibit, restrict or otherwise affect the terms and conditions
that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US
Dollar |
1 |
Rs.44.86 |
|
UK
Pound |
1 |
Rs.84.97 |
|
Euro |
1 |
Rs.57.59 |
SCORE &
RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
3 |
|
PAID-UP CAPITAL |
1~10 |
3 |
|
OPERATING SCALE |
1~10 |
3 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
3 |
|
--PROFITABILIRY |
1~10 |
- |
|
--LIQUIDITY |
1~10 |
- |
|
--LEVERAGE |
1~10 |
2 |
|
--RESERVES |
1~10 |
- |
|
--CREDIT LINES |
1~10 |
2 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
16 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit
history (10%) Market
trend (10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial
base with the strongest capability for timely payment of interest and
principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No
caution needed for credit transaction. It has above average (strong)
capability for payment of interest and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are
regarded healthy. General unfavourable factors will not cause fatal effect.
Satisfactory capability for payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal.
Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors
carry similar weight in credit consideration. Capability to overcome
financial difficulties seems comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of
interest and principal sums in default or expected to be in default upon
maturity |
Limited with full security |
|
<10 |
C |
Absolute credit risk exists. Caution
needed to be exercised |
Credit not recommended |
|
NR |
In view of the lack of information, we
have no basis upon which to recommend credit dealings |
No Rating |
|